 | • レポートコード：QYR9ST02372 • 出版社/出版日：QYResearch / 2019年9月2日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥569,400 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,138,800 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界のCINV既存・パイプライン薬市場について調査・分析し、以下の構成でお届け致します。CINV既存・パイプライン薬の種類別には、Aloxi（パロノセトロン）、Zofran Generic（オンダンセトロン）、Kytril Generic（グラニセトロン）、Emend（アプレピタント）、Akynzeo（ネツピタント・パロノセトロン）、SUSTOL（徐放性グラニセトロン注射）、Rolapitantに、用途別には、病院、専門クリニック、診断センター、治療薬、病院薬局、ドラッグストアに、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別CINV既存・パイプライン薬売上データ ・地域別CINV既存・パイプライン薬市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別CINV既存・パイプライン薬市場規模：Aloxi（パロノセトロン）、Zofran Generic（オンダンセトロン）、Kytril Generic（グラニセトロン）、Emend（アプレピタント）、Akynzeo（ネツピタント・パロノセトロン）、SUSTOL（徐放性グラニセトロン注射）、Rolapitant ・用途別CINV既存・パイプライン薬市場規模：病院、専門クリニック、診断センター、治療薬、病院薬局、ドラッグストア ・主要メーカーの企業情報：GlaxoSmithKline、Helsinn、Heron Therapeutics、Merck、Tesaro ・CINV既存・パイプライン薬の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).The global CINV Existing and Pipeline Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the CINV Existing and Pipeline Drugs market based on company, product type, end user and key regions.
This report studies the global market size of CINV Existing and Pipeline Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of CINV Existing and Pipeline Drugs in these regions.
This research report categorizes the global CINV Existing and Pipeline Drugs market by top players/brands, region, type and end user. This report also studies the global CINV Existing and Pipeline Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Market size by Product
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant
Market size by End User
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global CINV Existing and Pipeline Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of CINV Existing and Pipeline Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global CINV Existing and Pipeline Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of CINV Existing and Pipeline Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of CINV Existing and Pipeline Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Kg). Both top-down and bottom-up approaches have been used to estimate and validate the market size of CINV Existing and Pipeline Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 CINV Existing and Pipeline Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Product
1.4.2 Aloxi (palonosetron)
1.4.3 Zofran Generic (ondansetron)
1.4.4 Kytril Generic (granisetron)
1.4.5 Emend (aprepitant)
1.4.6 Akynzeo (netupitant-palonosetron)
1.4.7 SUSTOL (extended release granisetron injection)
1.4.8 Rolapitant
1.5 Market by End User
1.5.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.5.4 Diagnostic Centers Therapeutics
1.5.5 Hospital Pharmacies
1.5.6 Drugstores
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global CINV Existing and Pipeline Drugs Market Size
2.1.1 Global CINV Existing and Pipeline Drugs Revenue 2014-2025
2.1.2 Global CINV Existing and Pipeline Drugs Sales 2014-2025
2.2 CINV Existing and Pipeline Drugs Growth Rate by Regions
2.2.1 Global CINV Existing and Pipeline Drugs Sales by Regions
2.2.2 Global CINV Existing and Pipeline Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 CINV Existing and Pipeline Drugs Sales by Manufacturers
3.1.1 CINV Existing and Pipeline Drugs Sales by Manufacturers
3.1.2 CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers
3.1.3 Global CINV Existing and Pipeline Drugs Market Concentration Ratio (CR5 and HHI)
3.2 CINV Existing and Pipeline Drugs Revenue by Manufacturers
3.2.1 CINV Existing and Pipeline Drugs Revenue by Manufacturers (2014-2019)
3.2.2 CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2014-2019)
3.3 CINV Existing and Pipeline Drugs Price by Manufacturers
3.4 CINV Existing and Pipeline Drugs Manufacturing Base Distribution, Product Types
3.4.1 CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers CINV Existing and Pipeline Drugs Product Type
3.4.3 Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global CINV Existing and Pipeline Drugs Sales by Product
4.2 Global CINV Existing and Pipeline Drugs Revenue by Product
4.3 CINV Existing and Pipeline Drugs Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global CINV Existing and Pipeline Drugs Breakdown Data by End User
6 North America
6.1 North America CINV Existing and Pipeline Drugs by Countries
6.1.1 North America CINV Existing and Pipeline Drugs Sales by Countries
6.1.2 North America CINV Existing and Pipeline Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America CINV Existing and Pipeline Drugs by Product
6.3 North America CINV Existing and Pipeline Drugs by End User
7 Europe
7.1 Europe CINV Existing and Pipeline Drugs by Countries
7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Countries
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe CINV Existing and Pipeline Drugs by Product
7.3 Europe CINV Existing and Pipeline Drugs by End User
8 Asia Pacific
8.1 Asia Pacific CINV Existing and Pipeline Drugs by Countries
8.1.1 Asia Pacific CINV Existing and Pipeline Drugs Sales by Countries
8.1.2 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific CINV Existing and Pipeline Drugs by Product
8.3 Asia Pacific CINV Existing and Pipeline Drugs by End User
9 Central & South America
9.1 Central & South America CINV Existing and Pipeline Drugs by Countries
9.1.1 Central & South America CINV Existing and Pipeline Drugs Sales by Countries
9.1.2 Central & South America CINV Existing and Pipeline Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America CINV Existing and Pipeline Drugs by Product
9.3 Central & South America CINV Existing and Pipeline Drugs by End User
10 Middle East and Africa
10.1 Middle East and Africa CINV Existing and Pipeline Drugs by Countries
10.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Countries
10.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa CINV Existing and Pipeline Drugs by Product
10.3 Middle East and Africa CINV Existing and Pipeline Drugs by End User
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 Company Business Overview
11.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
11.1.5 GlaxoSmithKline Recent Development
11.2 Helsinn
11.2.1 Helsinn Company Details
11.2.2 Company Business Overview
11.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Helsinn CINV Existing and Pipeline Drugs Products Offered
11.2.5 Helsinn Recent Development
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Details
11.3.2 Company Business Overview
11.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products Offered
11.3.5 Heron Therapeutics Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Company Business Overview
11.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Merck CINV Existing and Pipeline Drugs Products Offered
11.4.5 Merck Recent Development
11.5 Tesaro
11.5.1 Tesaro Company Details
11.5.2 Company Business Overview
11.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Tesaro CINV Existing and Pipeline Drugs Products Offered
11.5.5 Tesaro Recent Development
12 Future Forecast
12.1 CINV Existing and Pipeline Drugs Market Forecast by Regions
12.1.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Regions 2019-2025
12.2 CINV Existing and Pipeline Drugs Market Forecast by Product
12.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Product 2019-2025
12.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Product 2019-2025
12.3 CINV Existing and Pipeline Drugs Market Forecast by End User
12.4 North America CINV Existing and Pipeline Drugs Forecast
12.5 Europe CINV Existing and Pipeline Drugs Forecast
12.6 Asia Pacific CINV Existing and Pipeline Drugs Forecast
12.7 Central & South America CINV Existing and Pipeline Drugs Forecast
12.8 Middle East and Africa CINV Existing and Pipeline Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 CINV Existing and Pipeline Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure CINV Existing and Pipeline Drugs Product Picture
Table CINV Existing and Pipeline Drugs Market Segments
Table Key Manufacturers CINV Existing and Pipeline Drugs Covered
Table Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Product 2019-2025 (Kg) & (Million US$)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Product 2014-2025
Figure Aloxi (palonosetron) Product Picture
Table Major Manufacturers of Aloxi (palonosetron)
Figure Zofran Generic (ondansetron) Product Picture
Table Major Manufacturers of Zofran Generic (ondansetron)
Figure Kytril Generic (granisetron) Product Picture
Table Major Manufacturers of Kytril Generic (granisetron)
Figure Emend (aprepitant) Product Picture
Table Major Manufacturers of Emend (aprepitant)
Figure Akynzeo (netupitant-palonosetron) Product Picture
Table Major Manufacturers of Akynzeo (netupitant-palonosetron)
Figure SUSTOL (extended release granisetron injection) Product Picture
Table Major Manufacturers of SUSTOL (extended release granisetron injection)
Figure Rolapitant Product Picture
Table Major Manufacturers of Rolapitant
Table Global CINV Existing and Pipeline Drugs Market Size Growth Rate by End User 2019-2025 (Kg)
Figure Hospitals
Figure Specialty Clinics
Figure Diagnostic Centers Therapeutics
Figure Hospital Pharmacies
Figure Drugstores
Figure CINV Existing and Pipeline Drugs Report Years Considered
Figure Global CINV Existing and Pipeline Drugs Market Size 2014-2025 (Million US$)
Figure Global CINV Existing and Pipeline Drugs Sales 2014-2025 (Kg)
Table Global CINV Existing and Pipeline Drugs Market Size by Regions 2014-2019 (Kg) & (Million US$)
Table Global CINV Existing and Pipeline Drugs Sales by Regions 2014-2019 (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Market Share by Regions 2014-2019
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Regions 2014-2019
Figure 2018 Global CINV Existing and Pipeline Drugs Sales Market Share by Regions
Table Global CINV Existing and Pipeline Drugs Revenue by Regions 2014-2019 (Million US$)
Table Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions 2014-2019
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions 2014-2019
Figure 2018 Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions
Table Global CINV Existing and Pipeline Drugs Sales by Manufacturers (2014-2019) (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Share by Manufacturers (2014-2019)
Figure Global CINV Existing and Pipeline Drugs Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table CINV Existing and Pipeline Drugs Revenue by Manufacturers (2014-2019) (Million USD)
Table CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2014-2019)
Figure CINV Existing and Pipeline Drugs Value Share by Manufacturers in 2018
Table Key Manufacturers CINV Existing and Pipeline Drugs Price (2014-2019) (USD/Kg)
Table CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers CINV Existing and Pipeline Drugs Product Type
Table Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global CINV Existing and Pipeline Drugs Sales by Product (2014-2019) (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Share by Product (2014-2019)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Product (2014-2019)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Product in 2018
Table Global CINV Existing and Pipeline Drugs Revenue by Product (2014-2019) (Million US$)
Table Global CINV Existing and Pipeline Drugs Revenue Share by Product (2014-2019)
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Product (2014-2019)
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Product in 2018
Table CINV Existing and Pipeline Drugs Price by Product 2014-2019 (USD/Kg)
Table Global CINV Existing and Pipeline Drugs Sales by End User (2014-2019) (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Share by End User (2014-2019)
Figure Global Sales CINV Existing and Pipeline Drugs Market Share by End User (2014-2019)
Figure Global Sales CINV Existing and Pipeline Drugs Market Share by End User in 2018
Figure North America CINV Existing and Pipeline Drugs Sales Growth Rate 2014-2019 (Kg)
Figure North America CINV Existing and Pipeline Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table North America CINV Existing and Pipeline Drugs Sales by Countries (2014-2019) (Kg)
Table North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 North America CINV Existing and Pipeline Drugs Sales Market Share by Countries
Table North America CINV Existing and Pipeline Drugs Revenue by Countries (2014-2019) (Million US$)
Table North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries
Figure United States CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure United States CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Kg)
Figure Canada CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Canada CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Mexico CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table North America CINV Existing and Pipeline Drugs Sales by Product (2014-2019) (Kg)
Table North America CINV Existing and Pipeline Drugs Sales Market Share by Product (2014-2019)
Figure 2018 North America CINV Existing and Pipeline Drugs Market Share by Product
Table North America CINV Existing and Pipeline Drugs Sales by End User (2014-2019) (Kg)
Table North America CINV Existing and Pipeline Drugs Sales Market Share by End User (2014-2019)
Figure 2018 North America CINV Existing and Pipeline Drugs Market Share by End User
Figure Europe CINV Existing and Pipeline Drugs Sales Growth Rate 2014-2019 (Kg)
Figure Europe CINV Existing and Pipeline Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Europe CINV Existing and Pipeline Drugs Sales by Countries (2014-2019) (Kg)
Table Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries
Table Europe CINV Existing and Pipeline Drugs Revenue by Countries (2014-2019) (Million US$)
Table Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries
Figure Germany CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Germany CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure France CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure France CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure UK CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure UK CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Italy CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Russia CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Europe CINV Existing and Pipeline Drugs Sales by Product (2014-2019) (Kg)
Table Europe CINV Existing and Pipeline Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Europe CINV Existing and Pipeline Drugs Market Share by Product
Table Europe CINV Existing and Pipeline Drugs Sales by End User (2014-2019) (Kg)
Table Europe CINV Existing and Pipeline Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Europe CINV Existing and Pipeline Drugs Market Share by End User
Figure Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate 2014-2019 (Kg)
Figure Asia Pacific CINV Existing and Pipeline Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific CINV Existing and Pipeline Drugs Sales by Countries (2014-2019) (Kg)
Table Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries
Table Asia Pacific CINV Existing and Pipeline Drugs Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Countries
Figure China CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure China CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Japan CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Korea CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure India CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure India CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Australia CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Indonesia CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Malaysia CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Philippines CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Thailand CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Vietnam CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Singapore CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific CINV Existing and Pipeline Drugs Sales by Product (2014-2019) (Kg)
Table Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific CINV Existing and Pipeline Drugs Market Share by Product
Table Asia Pacific CINV Existing and Pipeline Drugs Sales by End User (2014-2019) (Kg)
Table Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific CINV Existing and Pipeline Drugs Market Share by End User
Figure Central & South America CINV Existing and Pipeline Drugs Sales Growth Rate 2014-2019 (Kg)
Figure Central & South America CINV Existing and Pipeline Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America CINV Existing and Pipeline Drugs Sales by Countries (2014-2019) (Kg)
Table Central & South America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America CINV Existing and Pipeline Drugs Sales Market Share by Countries
Table Central & South America CINV Existing and Pipeline Drugs Revenue by Countries (2014-2019) (Million US$)
Table Central & South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries
Figure Brazil CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Brazil CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Argentina CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America CINV Existing and Pipeline Drugs Sales by Product (2014-2019) (Kg)
Table Central & South America CINV Existing and Pipeline Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America CINV Existing and Pipeline Drugs Market Share by Product
Table Central & South America CINV Existing and Pipeline Drugs Sales by End User (2014-2019) (Kg)
Table Central & South America CINV Existing and Pipeline Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America CINV Existing and Pipeline Drugs Market Share by End User
Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate 2014-2019 (Kg)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by Countries (2014-2019) (Kg)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries
Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries
Figure GCC Countries CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure GCC Countries CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Turkey CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure Egypt CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa CINV Existing and Pipeline Drugs Sales Growth Rate (2014-2019) (Kg)
Figure South Africa CINV Existing and Pipeline Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by Product (2014-2019) (Kg)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa CINV Existing and Pipeline Drugs Market Share by Product
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by End User (2014-2019) (Kg)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa CINV Existing and Pipeline Drugs Market Share by End User
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2014-2019)
Table GlaxoSmithKline Recent Development
Table Helsinn Company Details
Table Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2014-2019)
Table Helsinn Recent Development
Table Heron Therapeutics Company Details
Table Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2014-2019)
Table Heron Therapeutics Recent Development
Table Merck Company Details
Table Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2014-2019)
Table Merck Recent Development
Table Tesaro Company Details
Table Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2014-2019)
Table Tesaro Recent Development
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Regions 2019-2025 (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Regions 2019-2025
Table Global CINV Existing and Pipeline Drugs Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Regions 2019-2025
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Product 2019-2025 (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Product 2019-2025
Table Global CINV Existing and Pipeline Drugs Revenue Forecast by Product 2019-2025 (Million US$)
Table Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Product 2019-2025
Table Global CINV Existing and Pipeline Drugs Sales Forecast by End User 2019-2025 (Kg)
Table Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by End User 2019-2025
Figure North America CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2019-2025) (Kg)
Figure North America CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2019-2025) (Kg)
Figure Europe CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2019-2025) (Kg)
Figure Asia Pacific CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2019-2025) (Kg)
Figure Central & South America CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2019-2025) (Kg)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table CINV Existing and Pipeline Drugs Value Chain
Table CINV Existing and Pipeline Drugs Customers List
Table CINV Existing and Pipeline Drugs Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
ネツピタント-パロノセトロンFDCの世界市場：市場規模・現状・予測 The netupitant-palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance, which prevents chemotherapy-indu…- ネツピタント-パロノセトロンFDCの世界市場：市場規模・現状・予測 The netupitant-palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance, which prevents chemotherapy-indu…
- 世界の化学療法による吐き気・嘔吐（CINV）治療薬市場：専門的調査 Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs i…
- 世界の化学療法による吐き気・嘔吐（CINV）治療薬市場：専門的調査 Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs i…
- 世界のオンコロジージェネリック注射薬市場：専門的調査 Generic drugs are essential in oncology because some anticancer drugs are only available as generics. The global Oncology Generic Injectable Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focu…